- Home
- CVR vs KPRX Comparison
CVR vs KPRX Comparison
Compare CVR & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVR
- KPRX
- Stock Information
- Founded
- CVR 1920
- KPRX 1998
- Country
- CVR United States
- KPRX United States
- Employees
- CVR N/A
- KPRX N/A
- Industry
- CVR Industrial Machinery/Components
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CVR Industrials
- KPRX Health Care
- Exchange
- CVR Nasdaq
- KPRX Nasdaq
- Market Cap
- CVR 14.9M
- KPRX 9.8M
- IPO Year
- CVR N/A
- KPRX N/A
- Fundamental
- Price
- CVR $15.00
- KPRX $3.25
- Analyst Decision
- CVR
- KPRX Strong Buy
- Analyst Count
- CVR 0
- KPRX 1
- Target Price
- CVR N/A
- KPRX $10.00
- AVG Volume (30 Days)
- CVR 1.8K
- KPRX 41.6K
- Earning Date
- CVR 03-27-2025
- KPRX 03-24-2025
- Dividend Yield
- CVR 0.84%
- KPRX N/A
- EPS Growth
- CVR N/A
- KPRX N/A
- EPS
- CVR N/A
- KPRX 1.69
- Revenue
- CVR $29,663,473.00
- KPRX $16,020,000.00
- Revenue This Year
- CVR N/A
- KPRX N/A
- Revenue Next Year
- CVR N/A
- KPRX N/A
- P/E Ratio
- CVR N/A
- KPRX $1.88
- Revenue Growth
- CVR N/A
- KPRX N/A
- 52 Week Low
- CVR $13.40
- KPRX $2.91
- 52 Week High
- CVR $22.27
- KPRX $6.48
- Technical
- Relative Strength Index (RSI)
- CVR 55.06
- KPRX 43.58
- Support Level
- CVR $13.40
- KPRX $3.07
- Resistance Level
- CVR $14.79
- KPRX $3.26
- Average True Range (ATR)
- CVR 0.45
- KPRX 0.16
- MACD
- CVR 0.06
- KPRX 0.00
- Stochastic Oscillator
- CVR 100.00
- KPRX 45.25
About CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment. Geographically, the majority is from the United States.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.